BiomX addresses FDA queries on nebulizer for CF treatment
PositiveFinancial Markets

BiomX has successfully addressed the FDA's queries regarding its nebulizer designed for cystic fibrosis (CF) treatment. This is a significant step forward as it indicates the company's commitment to ensuring the safety and efficacy of its product. The approval of this nebulizer could provide a new and effective treatment option for CF patients, improving their quality of life and potentially changing the landscape of CF management.
— Curated by the World Pulse Now AI Editorial System